Experience of nonsteroidal antiandrogen therapy in patients with locally advanced and metastatic prostate cancer

The paper presents the results of treatment of 57 patients with locally advanced and metastatic prostatic carcinoma (PC) (T₃Р₄N₀M₀, T₁Р₄N₁M₀, T₁Р₄N₀M₁, and T₁Р₄N₁M₁) (mean age 64.2±7.1 years) with Russian nonsteroidal antiandrogen Bilumide® at a dose of 50 mg/day for the maximum androgenic block after bilateral orchiectomy. The efficacy and safety of the drug were evaluated by the IPSS and QoL scales, laboratory and ultrasound studies, as well as osteoscintigraphy and uroflowmetry. The open-labeled non-comparative studies indicated the clinical effectiveness and safety of Bilumide that can be recommended for the treatment of locally advanced and metastatic PC. Further studies to compare Bilumide® with other antiandrogens commonly used in practice are required.